| Revenue growth | 13.7% YoY increase in Total Income. |
|---|---|
| Margins | EBITDA margin at 36.4%; PAT margin at 18.6%. |
| Demand visibility | High demand for drug discovery and electronics testing services. |
Growth
Revenue hit ₹1,129 Mn (up 13.7% YoY). PAT grew 11.4% YoY to ₹210 Mn.
Outlook
Invested ₹180 Mn in CAPEX during Q1; historical 4-year revenue CAGR stands at 10.5%.
Risks
Economic volatility, currency fluctuations, and increasing competition in the CRTO industry.
Last quarter's promises, checked
Delivered
- Guided 35% EBITDA margin → delivered 36.4% (= BEAT)
- Targeted double-digit revenue growth → delivered 13.7% (= BEAT)
- Maintain net debt-free status → delivered 0.01 D/E (= BEAT)
Partly delivered
- Commence Biologics services in FY27 → Started with ₹180 Mn CAPEX/infrastructure (= PARTIAL)
Missed
- Targeted ₹500 Cr annualized run rate by Q4 FY26 → delivered ₹416.3 Cr (= MISS)
Earnings Call filed with BSE, NSE: VIMTALABS. Summary written with AI assistance from the document.
Vimta Labs Ltd: key numbers
- Share price
- ₹599.30
- Market cap
- ₹2,679 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 33.6×Sector 57.8×
- Promoter holding
- 35.67%-0.18% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Investor Presentation: Key Takeaways
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
- Call
- Guides 25% growth
Vimta Labs Q1 FY27 Results: Net Profit ₹21 Cr, Up 11.1% YoY
Vimta Labs Ltd reported revenue from operations of ₹109.1 Cr (+11.8% YoY) and net profit of ₹21 Cr (+11.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹21 Cr · +11.1% YoY
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reported Q4 FY26 revenue of ₹1,120 Mn and PAT of ₹211 Mn with strong margins across TIC segments.